LivaNova (LivaNova) Accounts Receivable

: $215 Mil (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. LivaNova's accounts receivables for the quarter that ended in Dec. 2023 was $215 Mil.

Accounts receivable can be measured by Days Sales Outstanding. LivaNova's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 63.28.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. LivaNova's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-12.06.

LivaNova Accounts Receivable Historical Data

The historical data trend for LivaNova's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LivaNova Annual Data

Trend

Apr14

Apr15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

257.77

184.36

185.35

183.11

215.07

LivaNova Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Receivable																183.11	178.32	185.88	189.87	215.07

LivaNova Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

LivaNova Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

LivaNova's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	215.072	/	310.132	*	91
=	63.28

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), LivaNova's accounts receivable are only considered to be worth 75% of book value:

LivaNova's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(266.504	+	0.75 * 215.072	+	0.5 * 147.887	-	1151.935
-	0	-	0)	/	53.9182
=	-12.06

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

LivaNova Accounts Receivable Related Terms

Thank you for viewing the detailed overview of LivaNova's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

LivaNova (LivaNova) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LivaNova PLC (NAS:LIVN) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

LIA:Germany

Address

20 Eastbourne Terrace, London, GBR, W2 6LG

Website

https://www.livanova.com

U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.

Executives

James Christopher Barry	director	7475 LUSK BLVD, SAN DIEGO CA 92121
Damien Mcdonald	officer: COO	5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Michael Damon Hutchinson	officer: Chief Legal Officer	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Brooke Story	director	C/O SIGILON THERAPEUTICS, INC., 100 BINNEY STREET, SUITE 600, CAMBRIDGE MA 02142
Peter M Wilver	director
Daniel Jeffrey Moore	director	100 CYBERONICS BVLD, HOUSTON TX 77058
Alfred J Novak	director	325 NE 6TH ST, BOCA RATON FL 33432
William A Kozy	director	C/O BECTON DICKERSON & CO, 1 BECTON DR, FRANKLIN LAKES NJ 07417
Marco Dolci	officer: SVP Global Operations, R&D	VIA BENIGNO CRESPI 17, MILAN L6 20159
Todd C Schermerhorn	director	C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
Alex Shvartsburg	officer: Interim CFO	20 EASTBOURNE TERRACE, LONDON X0 W26LG
Roy Khoury	officer: President, International	5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Thad Allen Huston	officer: Chief Financial Officer	941 BLOOMFIELD ST, HOBOKEN NJ 07030
Seng Stacy Enxing	director	C/O HILL-ROM HOLDINGS, INC., SUITE 4100 180 NORTH STETSON AVENUE, CHICAGO IL 60601
Trui Hebbelinck	officer: Chief Human Resources Officer	20 EASTBOURNE TERRACE, LONDON X0 W2 6LG